HK1154797A1 - 治療疾病的成分 - Google Patents

治療疾病的成分

Info

Publication number
HK1154797A1
HK1154797A1 HK11109118.5A HK11109118A HK1154797A1 HK 1154797 A1 HK1154797 A1 HK 1154797A1 HK 11109118 A HK11109118 A HK 11109118A HK 1154797 A1 HK1154797 A1 HK 1154797A1
Authority
HK
Hong Kong
Prior art keywords
composition
treating disease
disease
treating
Prior art date
Application number
HK11109118.5A
Other languages
English (en)
Inventor
Frank Osterroth
Silke Aigner
Christoph Uherek
Andrea Wartenberg-Demand
Anatoly Rudnev
Michael Soldan
Christoph Bruecher
Benjamin Daelken
Chantal Zuber
Gregor Schulz
Niklas Czeloth
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0817811A external-priority patent/GB0817811D0/en
Priority claimed from GB0817810A external-priority patent/GB0817810D0/en
Priority claimed from GB0817809A external-priority patent/GB0817809D0/en
Priority claimed from PCT/EP2009/052809 external-priority patent/WO2009121690A1/en
Priority claimed from PCT/EP2009/052810 external-priority patent/WO2009112502A1/en
Priority claimed from PCT/EP2009/052811 external-priority patent/WO2009124815A1/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of HK1154797A1 publication Critical patent/HK1154797A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
HK11109118.5A 2008-09-29 2011-08-29 治療疾病的成分 HK1154797A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0817811A GB0817811D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817810A GB0817810D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
GB0817809A GB0817809D0 (en) 2008-09-29 2008-09-29 Agent for treating disease
PCT/EP2009/052809 WO2009121690A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
PCT/EP2009/052810 WO2009112502A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
PCT/EP2009/052811 WO2009124815A1 (en) 2008-03-13 2009-03-10 Agent for treating disease
PCT/EP2009/061210 WO2010034590A1 (en) 2008-09-29 2009-08-31 Composition for treating disease

Publications (1)

Publication Number Publication Date
HK1154797A1 true HK1154797A1 (zh) 2012-05-04

Family

ID=41138980

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11109118.5A HK1154797A1 (zh) 2008-09-29 2011-08-29 治療疾病的成分

Country Status (17)

Country Link
US (1) US20110229465A1 (zh)
JP (2) JP2012504110A (zh)
KR (1) KR20110061630A (zh)
CN (1) CN102215867B (zh)
AU (1) AU2009296078B2 (zh)
BR (1) BRPI0919489A2 (zh)
CA (1) CA2738598C (zh)
CR (1) CR20110226A (zh)
DK (1) DK2341937T3 (zh)
ES (1) ES2528419T3 (zh)
HK (1) HK1154797A1 (zh)
IL (1) IL211904A (zh)
MX (1) MX2011003335A (zh)
PT (1) PT2341937E (zh)
RU (1) RU2531548C2 (zh)
SG (1) SG194362A1 (zh)
WO (1) WO2010034590A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
SG190627A1 (en) * 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
JP5597553B2 (ja) * 2008-03-13 2014-10-01 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
CA2718191C (en) * 2008-03-13 2018-05-15 Biotest Ag Agent for treating disease
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20160158352A1 (en) * 2013-07-10 2016-06-09 The United States of America, as represented by the Secretary, Department of Health & Human Servic Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans
GB202017681D0 (en) * 2020-11-09 2020-12-23 T Balance Therapeutics Gmbh Anti-CD4 antibody or fragment thereof for medical use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US20020099179A1 (en) * 1989-12-21 2002-07-25 Linda K. Jolliffe Cdr-grafted antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
CA2073031C (en) * 1990-11-27 2002-10-01 Linda C. Burkly Anti-cd4 antibody homologs useful in prophylaxis and treatment of aids, arc and hiv infection
US7192584B2 (en) * 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JPH05244982A (ja) * 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5777085A (en) * 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
DE122009000074I1 (de) * 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
EP0631783A1 (en) * 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US20020068057A1 (en) * 1994-03-10 2002-06-06 Marc Feldmann Treatment of autoimmune and inflammatory disorders
US20010056066A1 (en) * 1996-07-26 2001-12-27 Smithkline Beecham Corporation Method of treating immune cell mediated systemic diseases
DE19722888A1 (de) * 1997-05-28 1998-12-03 Thomas Prof Dr Huenig Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten
DE05075555T1 (de) * 1999-06-09 2007-02-08 Immunomedics, Inc. Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern
WO2001093908A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of Minnesota Immunotherapeutic method to prevent islet cell rejection
CN1592645A (zh) * 2000-09-18 2005-03-09 拜奥根Idec公司 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
DE10050935A1 (de) * 2000-10-11 2002-05-02 Tegenero Gmbh Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
EP2314293B1 (en) * 2001-01-16 2017-01-04 Vascular Therapies, LLC Implantable device containing resorbable matrix material and rapamycin for preventing or treating vasuloproliferative diseases
AU2002254134B2 (en) * 2001-03-07 2006-06-01 Children's Medical Center Corporation Method to screen peptide display libraries using minicell display
MXPA03009683A (es) * 2001-04-24 2004-02-12 Merck Patent Gmbh TERAPIA EN COMBINACIoN USANDO AGENTES ANTIANGIOGENICOS Y FACTOR DE NECROSIS TUMORAL ALFA.
US7541443B2 (en) * 2001-06-14 2009-06-02 Tolerrx, Inc. Anti-CD4 antibodies
EP1451224B1 (de) * 2001-12-04 2012-08-15 TheraMAB LLC Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie
DE10212108A1 (de) * 2002-03-13 2003-10-02 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE10230223A1 (de) * 2002-07-04 2004-01-22 Tegenero Ag Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
US7501494B2 (en) * 2003-01-15 2009-03-10 United Biomedical, Inc. Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
PL1613350T3 (pl) * 2003-04-09 2009-08-31 Genentech Inc Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα
GB0314461D0 (en) * 2003-06-20 2003-07-23 Isis Innovation Suppression of transplant rejection
EP1600164A3 (de) * 2003-09-22 2006-05-17 TeGenero AG Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10352900A1 (de) * 2003-11-11 2005-06-16 Tegenero Ag Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
CN101031305A (zh) * 2004-09-29 2007-09-05 兴和株式会社 类风湿性关节炎的预防和/或治疗药物
DE102004063494A1 (de) * 2004-12-23 2006-07-13 Tegenero Ag Antikörper
JP4730733B2 (ja) * 2005-05-02 2011-07-20 国立大学法人京都大学 ４型葉酸受容体の発現を指標とした制御性ｔ細胞の検出方法、及び免疫賦活剤
US8663634B2 (en) * 2005-07-11 2014-03-04 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
KR101460932B1 (ko) * 2005-08-26 2014-11-12 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
CA2645322A1 (en) * 2006-03-16 2007-09-27 Genentech, Inc. Methods of treating lupus using cd4 antibodies
SG190627A1 (en) 2008-03-13 2013-06-28 Biotest Ag Agent for treating disease
JP5597553B2 (ja) 2008-03-13 2014-10-01 バイオテスト・アクチエンゲゼルシヤフト 疾患治療剤
CA2718191C (en) * 2008-03-13 2018-05-15 Biotest Ag Agent for treating disease
ES2351456B1 (es) * 2009-06-24 2011-11-28 Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b

Also Published As

Publication number Publication date
IL211904A (en) 2016-03-31
JP2015172060A (ja) 2015-10-01
RU2011117293A (ru) 2012-11-10
PT2341937E (pt) 2015-02-18
RU2531548C2 (ru) 2014-10-20
CA2738598A1 (en) 2010-04-01
JP6154847B2 (ja) 2017-06-28
CN102215867B (zh) 2017-04-19
CA2738598C (en) 2017-11-21
US20110229465A1 (en) 2011-09-22
ES2528419T3 (es) 2015-02-09
WO2010034590A1 (en) 2010-04-01
CN102215867A (zh) 2011-10-12
AU2009296078B2 (en) 2015-08-20
IL211904A0 (en) 2011-06-30
JP2012504110A (ja) 2012-02-16
CR20110226A (es) 2011-12-05
SG194362A1 (en) 2013-11-29
BRPI0919489A2 (pt) 2015-12-01
AU2009296078A1 (en) 2010-04-01
KR20110061630A (ko) 2011-06-09
MX2011003335A (es) 2011-04-27
DK2341937T3 (en) 2015-02-09

Similar Documents

Publication Publication Date Title
IL257418A (en) Methods for treating addiction
IL207892A0 (en) Agent for treating disease
HK1151533A1 (zh) 種治療疾病的試劑
ZA201007215B (en) Agent for treating disease
IL209895A0 (en) Compounds for treating beta-amyloidoses
EP2322076A4 (en) ENDOSCOPE OF TREATMENT
GB0802116D0 (en) Treatment
EP2282826A4 (en) PROCESS FOR TREATMENT OF ODOR
EP2365747A4 (en) METHODS OF TREATING GASTROINTESTINAL DISEASES
EP2341936A4 (en) METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
ZA201204845B (en) Agents for treating disease
HK1154797A1 (zh) 治療疾病的成分
TWI367274B (en) Composition for fabric treatment
GB0811992D0 (en) Treatment
SG10201408508YA (en) Combination composition useful for treating cardiovascular diseases
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
ZA201009226B (en) Nifurtimox for treating disease caused by trichomonadida
EP2255825A4 (en) COMPOSITION FOR PREVENTING OR TREATING BRAIN DISEASES
GB0805912D0 (en) Treatment
PL384259A1 (pl) Kompozycja farmaceutyczna do leczenia chorób skórnych
SI2341937T1 (sl) Sestavek za zdravljenje bolezni
GB0817809D0 (en) Agent for treating disease
GB0817811D0 (en) Agent for treating disease
GB0817810D0 (en) Agent for treating disease
GB0818713D0 (en) Substances useful for treating diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190903